Open clinical trial on the sigma ligand panamesine in patients with schizophrenia.

Authors :: Frieboes, R.-M.
Murck, Harald
Wiedemann, Klaus
Holsboer, Florian
Steiger, Axel
Source :: Psychopharmacology; 1997, Vol. 132 Issue 1, p82, 7p
Publication Year :: 1997
Abstract: The sigma (σ) receptor has been proposed as a target of neuroleptic drugs. Preclinical data suggest that panamesine (EMD 57445), a novel σ ligand, has antipsychotic effects and is free of side effects related to the extrapyramidal motoric system (EPMS)... [ABSTRACT FROM AUTHOR]

Subjects :: ANTIPSYCHOTIC agents
SCHIZOPHRENIA treatment
EXTRAPYRAMIDAL tracts
DRUG efficacy

Full Text Access

Tools